Peramivir IV for H1N1 Influenza

The Department of Health and Human Services (HHS) declared a Public Health Emergency on April 26, 2009 due to the 2009 H1N1 influenza virus (formerly known as the swine flu). From August 30 – October 17, 2009, 8,204 laboratory-confirmed influenza associated hospitalizations, 411 laboratory-confirmed influenza associated deaths, 21,823 pneumonia and influenza syndrome-based hospitalizations, and 2,416 pneumonia and influenza syndrome-based deaths, were reported to CDC.

On October 24, 2009, President Obama declared the 2009 H1N1 Pandemic a national emergency. Based on this declaration, the Secretary of HHS authorized the release of Peramivir IV under an Emergency Use Authorization. Peramivir is an intravenous neuraminidase inhibitor still in Phase 3 clinical trials. Pharmacists and other health care providers need a basic understanding of the indications, dosing, administration, and potential adverse events of Peramivir as well as procedures for obtaining the drug.

Description

This continuing pharmacy education activity was developed using the Emergency Use Authorization of Peramivir IV: Fact Sheet for Health care Providers to summarize critical information for pharmacy practitioners as well as other health care providers. Links to vital information resources and websites are also provided.

Target Audience

This program is intended for health system pharmacists, health care providers practicing in the acute care setting and other providers wishing to obtain more information on Peramivir IV.

Requirements

To receive continuing pharmacy education, the learner must register for the activity, view the online presentation, participate in the active learning, review the Resources, then complete the assessment and online evaluation.

There is no fee for this activity. After registering, go to Your Account and press Start next to the Peramivir activity to begin.

Courses Offered

Course	Contact Hours/CEUs
Peramivir IV for H1N1 Influenza(details)	1.0/0.1